Treatment-emergent grade 3/4 AEs occurring in ≥5% of patients (N = 44)
| . | Grades 3 or 4, n (%) . | Carfilzomib-related, n (%) . |
|---|---|---|
| Hematologic | ||
| Lymphopenia | 22 (50) | 19 (43) |
| Leukopenia | 19 (43) | 8 (18) |
| Thrombocytopenia | 17 (39) | 14 (32) |
| Anemia | 16 (36) | 8 (18) |
| Neutropenia | 10 (23) | 8 (18) |
| Nonhematologic | ||
| Hypertension | 11 (25) | 11 (25) |
| Heart failure* | 9 (20) | 5 (11) |
| LV systolic dysfunction | 6 (14) | 2 (5) |
| Pneumonia | 8 (18) | 8 (18) |
| Hypophosphatemia | 7 (16) | 2 (5) |
| Fatigue | 6 (14) | 2 (5) |
| Dyspnea | 5 (11) | 3 (7) |
| Hyponatremia | 5 (11) | 2 (5) |
| Hypocalcemia | 5 (11) | 2 (5) |
| Acute kidney injury | 4 (9) | 0 (0) |
| Neutropenic fever | 3 (7) | 1 (2) |
| ALT increased | 3 (7) | 3 (7) |
| AST increased | 3 (7) | 3 (7) |
| Hyperglycemia | 3 (7) | 0 (0) |
| . | Grades 3 or 4, n (%) . | Carfilzomib-related, n (%) . |
|---|---|---|
| Hematologic | ||
| Lymphopenia | 22 (50) | 19 (43) |
| Leukopenia | 19 (43) | 8 (18) |
| Thrombocytopenia | 17 (39) | 14 (32) |
| Anemia | 16 (36) | 8 (18) |
| Neutropenia | 10 (23) | 8 (18) |
| Nonhematologic | ||
| Hypertension | 11 (25) | 11 (25) |
| Heart failure* | 9 (20) | 5 (11) |
| LV systolic dysfunction | 6 (14) | 2 (5) |
| Pneumonia | 8 (18) | 8 (18) |
| Hypophosphatemia | 7 (16) | 2 (5) |
| Fatigue | 6 (14) | 2 (5) |
| Dyspnea | 5 (11) | 3 (7) |
| Hyponatremia | 5 (11) | 2 (5) |
| Hypocalcemia | 5 (11) | 2 (5) |
| Acute kidney injury | 4 (9) | 0 (0) |
| Neutropenic fever | 3 (7) | 1 (2) |
| ALT increased | 3 (7) | 3 (7) |
| AST increased | 3 (7) | 3 (7) |
| Hyperglycemia | 3 (7) | 0 (0) |
ALT, alanine aminotransferase; AST aspartate aminotransferase
Heart failure includes LV systolic dysfunction, pulmonary edema, and/or other criteria.